We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $0 invested in Acceleron Pharma in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 330 → 1 (-329)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less capital invested

Capital invested by funds: $9.13B → $0 (-$9.13B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 325

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-329
Holders Change %
-99.7%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
325
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$923M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$848M
3
ACA
Avoro Capital Advisors
New York
-$688M
4
BlackRock
BlackRock
New York
-$684M
5
FCM
Farallon Capital Management
California
-$373M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAC
201
OMERS Administration Corp
Ontario, Canada
– -$998K -5,800 Closed
PRC
202
Pearl River Capital
Michigan
– -$996K -5,789 Closed
OR
203
Olympiad Research
Connecticut
– -$984K -5,717 Closed
GH
204
GAM Holding
Switzerland
– -$981K -5,700 Closed
OAM
205
Oppenheimer Asset Management
New York
– -$960K -5,576 Closed
AWM
206
Avior Wealth Management
Nebraska
– -$940K -5,464 Closed
GI
207
GAMCO Investors
Connecticut
– -$926K -5,378 Closed
AG
208
Algert Global
California
– -$922K -5,358 Closed
BCM
209
BCK Capital Management
Connecticut
– -$861K -5,000 Closed
BCM
210
Bluefin Capital Management
New York
– -$858K -4,987 Closed
NICM
211
Neo Ivy Capital Management
New York
– -$432K -4,535 Closed
RPAM
212
Rhenman & Partners Asset Management
Sweden
– -$756K -4,392 Closed
DIA
213
Dana Investment Advisors
Wisconsin
– -$716K -4,160 Closed
MSRPS
214
Maryland State Retirement & Pension System
Maryland
– -$717K -4,102 Closed
BBHC
215
Brown Brothers Harriman & Co
New York
– -$688 -4,000 Closed
BPGAM
216
BTG Pactual Global Asset Management
Bermuda
– -$688K -4,000 Closed
GC
217
Grace Capital
Massachusetts
– -$695K -4,000 Closed
FC
218
FORA Capital
Florida
– -$668K -3,881 Closed
SCA
219
Sassicaia Capital Advisers
New York
– -$654K -3,800 Closed
EI
220
Ethic Inc
New York
– -$651K -3,785 Closed
PCM
221
Prelude Capital Management
New York
– -$635K -3,691 Closed
Nisa Investment Advisors
222
Nisa Investment Advisors
Missouri
– -$634 -3,686 Closed
JMPWA
223
JP Morgan Private Wealth Advisors
California
– -$618K -3,593 Closed
PI
224
PEAK6 Investments
Illinois
– -$616K -3,581 Closed
MLICM
225
Metropolitan Life Insurance Company (MetLife)
New York
– -$609K -3,537 Closed
7 8
9
10 11

XLRN Hedge Fund Activity: Q4 2021 in Review

1 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2021, worth a combined $0 — down 100% from $9.13B a quarter earlier.

Sellers outnumbered buyers: 325 funds closed out of XLRN and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $923M sold.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2021, down from 330 in Q3 2021.
  • Funds reported $0 of Acceleron Pharma stock for Q4 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Acceleron Pharma positions in Q4 2021 and 325 closed out, a net change of -325 holders.
  • The largest Acceleron Pharma seller in Q4 2021 was T. Rowe Price Associates, an estimated $923M sold.

Based on aggregated 13F filings for Q4 2021.